Trulicity Cost in Arkansas 2026: Prices, Insurance, Medicaid, and Compounding Options

What Is Trulicity and Why Does the Price Matter in Arkansas?

Dulaglutide, sold as Trulicity by Eli Lilly, is a once-weekly GLP-1 receptor agonist approved by the FDA for blood glucose management in adults with type 2 diabetes and for reducing major adverse cardiovascular events in adults with established cardiovascular disease or multiple risk factors [1]. Arkansas has one of the highest rates of diabetes in the United States. The CDC reports that approximately 12.9% of Arkansas adults have diagnosed diabetes, placing the state consistently in the top quartile nationally [2]. That burden makes the price of dulaglutide a direct public-health question, not an abstract billing detail.

The manufacturer list price of $931 per month is identical whether you walk into a pharmacy in Little Rock, Jonesboro, or Fort Smith. What differs is what you actually pay, based on your insurance tier, your Medicaid eligibility, and whether you access a compounding pharmacy. Understanding each pathway is the fastest route to the lowest out-of-pocket cost [3].

Dulaglutide works by mimicking the endogenous incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying [4]. The starting dose is 0.75 mg subcutaneously once weekly, with a standard titration to 1.5 mg after four weeks; doses of 3.0 mg and 4.5 mg are available for additional glycemic or weight benefit [1].

How Much Does Trulicity Cost in Arkansas Without Insurance?

Without any insurance or assistance program, the cash price for Trulicity in Arkansas is approximately $931 per month in 2026, consistent with Eli Lilly's wholesale acquisition cost. That figure covers a four-pen carton (four weekly doses). At that rate, annual spending exceeds $11,000 for uninsured patients paying full price [5].

Retail pharmacy prices show little meaningful variation across Arkansas zip codes because Trulicity has no generic equivalent. GoodRx and similar discount platforms negotiate moderate reductions, but savings rarely drop the price below $800 to $850 per month for the brand product at standard Arkansas pharmacies. A 90-day supply obtained through mail-order pharmacies sometimes yields a per-month cost 5 to 10 percent lower than a 30-day retail fill [6].

The FDA has not yet approved a generic or biosimilar dulaglutide as of mid-2025, so no substitutable lower-cost version exists at retail [7]. This distinguishes dulaglutide from older diabetes drugs such as metformin or glipizide, where generic pricing can reach under $10 per month. Patients with type 2 diabetes who cannot afford brand Trulicity have two realistic pathways: manufacturer financial assistance or a compounded preparation from a 503A pharmacy (discussed in a dedicated section below).

The HealthRX Cost Navigation Framework for Arkansas patients evaluating Trulicity expenses involves three sequential checks: (1) confirm insurance formulary placement and tier; (2) apply the Lilly savings card or patient assistance program if commercially insured or uninsured; (3) assess 503A compounded dulaglutide eligibility if out-of-pocket costs remain above an individual's threshold after steps one and two.

Does Arkansas Medicaid Cover Trulicity?

Arkansas Medicaid (Arkansas Works / ARHOME) covers dulaglutide for type 2 diabetes, but only after a prior authorization (PA) is approved [8]. The PA requirement is not automatic. Prescribers must document that the patient has a confirmed diagnosis of type 2 diabetes, that at least one first-line agent (typically metformin) was tried and either failed or was contraindicated, and that the requested dose is medically appropriate.

The Arkansas DHS Preferred Drug List places GLP-1 receptor agonists in a non-preferred tier in many benefit categories, meaning the PA process involves clinical criteria review rather than a simple step-therapy check [9]. Approval timelines vary: routine PA decisions are generally returned within 72 hours, but urgent requests can be processed in 24 hours under federal Medicaid rules [10].

For Medicaid enrollees who obtain PA approval, cost-sharing is minimal, often a nominal co-pay of $3 to $8 per fill depending on the specific Medicaid benefit category. The practical barrier is documentation. Prescribers who submit complete records (HbA1c values, prior medication trials, dates, and documented reasons for discontinuation) see substantially higher first-pass approval rates than those who submit incomplete prior authorization packets [11].

Arkansas Medicaid does not currently cover dulaglutide for weight management alone (off-label use), since the FDA indication for weight loss is held by semaglutide 2.4 mg (Wegovy), not dulaglutide [12]. Patients seeking a GLP-1 primarily for obesity management under Arkansas Medicaid face a different formulary pathway entirely.

Which Private Insurance Plans Cover Trulicity in Arkansas?

Most major commercial insurance carriers operating in Arkansas, including Arkansas Blue Cross Blue Shield, QualChoice, Ambetter from Home State Health, and UnitedHealthcare, include dulaglutide on formulary, typically at Tier 3 or Tier 4 [13]. Tier placement directly sets your co-insurance or co-pay.

A Tier 3 placement commonly means 30 to 50 percent co-insurance after the deductible, which on a $931 list price can still leave the patient paying $250 to $465 per month out of pocket once a deductible is met. Tier 4 specialty tier placement can mean even higher cost-sharing. Step therapy requirements, where the insurer requires documented trials of other antidiabetics before approving Trulicity, are common [14].

Employer-sponsored plans vary widely. Some Arkansas employers purchase pharmacy benefit designs that place GLP-1 drugs on open formulary with a flat $50 to $75 specialty co-pay. Others apply full deductibles before coverage begins. The most direct action a patient can take before filling a prescription is to call the member services number on the insurance card and ask: (a) what tier is dulaglutide on, (b) is a prior authorization required, and (c) is step therapy required and for how long.

For patients with commercial insurance whose plans cover Trulicity, the Eli Lilly savings card (described below) may reduce cost-sharing further, down to as little as $25 per month in eligible cases [15].

How Does the Eli Lilly Savings Card Work in Arkansas?

The Lilly Insulin Value Program and the Trulicity savings card are separate programs. For Trulicity specifically, Lilly offers a co-pay assistance card that can reduce monthly cost-sharing to as low as $25 per month for commercially insured patients who meet eligibility criteria [15]. The card is not available to patients covered by federal or state government insurance, including Medicare Part D, Medicaid, or TRICARE.

Enrollment is done online at LillyCares.com or through the prescriber's office. The card is loaded electronically and applied at the pharmacy counter. Arkansas pharmacies that participate in the card program include major chains (CVS, Walgreens, Walmart) and most independent pharmacies with standard PMS software capable of processing manufacturer co-pay cards [16].

For uninsured patients or those on government insurance who do not qualify for the co-pay card, Lilly's patient assistance program (Lilly Cares Foundation) may provide Trulicity at no cost. Income eligibility thresholds as of 2025 were set at or below 400% of the federal poverty level for the no-cost program, with a simplified application reviewed in approximately two to four weeks [17].

Patients on Medicare Part D who hit the catastrophic coverage threshold may find that out-of-pocket costs decrease substantially in the latter part of the benefit year because of the Inflation Reduction Act changes capping annual out-of-pocket drug costs at $2,000 starting in 2025 [18].

Is Compounded Dulaglutide Legal in Arkansas?

Compounded dulaglutide from a licensed 503A pharmacy is legally available to Arkansas patients with a valid prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on a prescription, even when an FDA-approved equivalent exists, provided the compounded preparation meets USP standards and is not commercially available in the exact formulation required [19].

Arkansas State Board of Pharmacy licenses and regulates 503A compounding pharmacies operating within the state [20]. Out-of-state 503A pharmacies shipping into Arkansas must hold a non-resident pharmacy permit from the Arkansas State Board of Pharmacy and comply with the same compounding standards.

Compounded dulaglutide is not FDA-approved, meaning it has not undergone the same safety, efficacy, and manufacturing review as brand Trulicity. Potency, sterility, and excipient composition may differ from the reference listed drug. The FDA has noted general concerns about the quality of compounded GLP-1 preparations across multiple warning letters issued in 2024 and 2025 [21]. Patients considering compounded dulaglutide should request a Certificate of Analysis from the compounding pharmacy confirming potency and sterility testing results on each batch [22].

Cost for compounded dulaglutide at licensed Arkansas 503A pharmacies varies by pharmacy, dose, and volume purchased. Some telehealth-affiliated compounding pharmacies have offered formulations at costs substantially below the $931 brand price. Patients should verify that any compounding pharmacy they use holds a current Arkansas non-resident permit or an in-state license before accepting a shipment [20].

Can I Get a Trulicity Prescription via Telehealth in Arkansas?

Yes. Arkansas law permits telehealth prescribing of non-controlled prescription drugs, including dulaglutide, when a valid prescriber-patient relationship is established through a synchronous video visit [23]. Audio-only telehealth visits do not satisfy the prescribing standard for new medications in Arkansas; a video encounter is required for the initial prescription.

Arkansas adopted the Interstate Medical Licensure Compact (IMLC), allowing physicians licensed in compact member states to see Arkansas patients via telehealth without separately obtaining an Arkansas license, provided they follow compact rules [24]. Nurse practitioners and physician assistants prescribing dulaglutide in Arkansas must hold either an Arkansas license or a valid compact state license and meet collaborative practice requirements under Arkansas Code Annotated 17-87-310.

Telehealth platforms that offer dulaglutide prescribing, including HealthRX, conduct video visits, review labs (including recent HbA1c, renal function, and lipid panel), and transmit electronic prescriptions directly to the patient's preferred Arkansas pharmacy or affiliated compounding pharmacy. This workflow is typically faster than scheduling an in-person endocrinology appointment, which in rural Arkansas counties can involve wait times of 60 to 120 days [25].

What Are the Clinical Benefits That Justify the Cost?

Dulaglutide's cost is easiest to evaluate against its documented outcomes. The REWIND trial (N=9,901, median follow-up 5.4 years, published Lancet 2019) showed that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, or cardiovascular death) by 12% compared to placebo (HR 0.88 to 95% CI 0.79 to 0.99, P<0.026) in adults with type 2 diabetes who had either established cardiovascular disease or multiple risk factors [26]. This was the first GLP-1 trial to show CV benefit in a population where more than 69% had no prior cardiovascular event, meaning the benefit extended to primary prevention of cardiovascular events in high-risk patients.

HbA1c reductions with dulaglutide range from approximately 1.1% to 1.6% from baseline across Phase 3 AWARD trials, depending on dose and baseline glycemia [27]. Body weight reductions average 3 to 4 kg at 1.5 mg weekly. At higher doses (4.5 mg), the AWARD-11 trial showed mean weight loss of 4.7 kg at 36 weeks [28].

The American Diabetes Association 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended" [29]. Dulaglutide satisfies that criterion based on REWIND data. For Arkansas patients with type 2 diabetes and cardiovascular risk factors, the clinical case for dulaglutide is supported by one of the largest cardiovascular outcomes trials in the GLP-1 class.

Gastrointestinal side effects, principally nausea, vomiting, and diarrhea, occur in 10 to 20% of patients initiating dulaglutide and are most prominent in the first four to eight weeks [1]. Starting at 0.75 mg and titrating no faster than every four weeks minimizes discontinuation from GI intolerance [30].

What Is the Cheapest Way to Get Trulicity in Arkansas?

For patients with commercial insurance, applying the Lilly savings card immediately after the prescription is written is the single fastest cost reduction, potentially bringing monthly cost to $25 [15]. For Medicaid-eligible patients, submitting a complete PA package with documented prior therapy failure cuts approval time and secures near-zero cost-sharing [11].

For uninsured patients above Medicaid income limits who do not qualify for the Lilly savings card, compounded dulaglutide from a licensed Arkansas 503A pharmacy currently offers the largest absolute price reduction relative to the $931 brand price, though patients accept the absence of FDA manufacturing oversight when choosing that route [19]. GoodRx discounts applied to brand Trulicity at pharmacies such as Walmart in Arkansas bring the price to roughly $830 to $880 per month, a modest reduction that does not change the fundamental affordability picture for most uninsured patients.

Switching to a therapeutically similar GLP-1 with better formulary placement is a legitimate clinical conversation. Semaglutide 0.5 mg or 1.0 mg (Ozempic) occupies a different Tier position on some Arkansas formularies and may carry lower co-insurance in some commercial plans [31]. That decision requires prescriber involvement to confirm therapeutic equivalence for the individual patient's clinical situation.